All In Biotech

Drug Trial Radar · NCT05367960

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

314

Actual

Start

Nov 1, 2022

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Tetra Discovery PartnersIndustry
Sponsor type
Industry
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 9 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).

Conditions

  • Fragile X Syndrome

Interventions

  • Zatolmilast/ BPN14770Drug

    25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of BPN14770Time frame: 24 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Amnova Clinical Research

    Irvine, California

  • Thompson Autism & Neurodevelopment Center - CHOC

    Orange, California

  • MIND Institute UC Davis Medical Center

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Miami

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • U Mass

    Worcester, Massachusetts

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Suburban Research Associates

    Media, Pennsylvania

  • Clinic for Special Children

    Strasburg, Pennsylvania

  • Greenwood Genetic Center

    Greenville, South Carolina

  • University of Utah and Primary Children's Hospital

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.